Curriculum Vitae
Family name: Jie
First names: Chen
Year of birth: July 24, 1977
Gender: Female
Working institution: Department of Social medicine and Maternal& Child Health, School of Public Health, Shandong University
Working experiences /Present position: Associate Professor
2013-to date Associate Professor, School of Public Health, Shandong University
2005-2013 Lecturer, School of Public Health, Shandong University
Education:
Institution (Date from - Date to) |
Degree(s) or Diploma(s) obtained: |
Stanford University, USA （2015.08-2016.08） |
Visiting scholar, OBGYN |
Shandong University, P.R. China (2000.09-2005.07) |
Ph.D (direct PhD program), School of Medicine |
Shandong University, P.R. China (1995.09-2000.07) |
M.B., School of Medicine |
Expertise/Research issues:
1) Study on genetic counseling, prenatal diagnosis and reproductive endocrine diseases in pregnant women.
2) Molecular identification and early screening of tumor markers; mechanism of carcinogenesis and metastasis of malignant maternal tumors.
Selected Research Projects as PIs:
1) Study on the role of EFEMP1-STEAP1 ligand receptor complex in the occurrence, development, prevention and treatment of ovarian cancer
Agency: Key R&D plan of Shandong Province
Funding period: August 1, 2018- June 30, 2019
1) Study on the mechanism of STEAP1 in carcinogenesis, development and angiogenesis of ovarian cancer
Agency: Shandong Natural Science Foundation of China
Funding period: August 1, 2017- June 30, 2020
2) The research about the role of EFEMP1 in ovarian cancer invasion, metastasis and angiogenesis
Agency: National Nature Science Foundation of China
Funding period: January 1, 2013- December 30, 2015
3)The role of fibulin-4 in the pathogenesis and development of ovarian cancer
Agency: China Postdoctoral Science Foundation
Funding period: January 1, 2013- December 30, 2014
Selected Publications：
1)Chen J, Zhang J, Zhao Y, Li J, Fu M. Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones. J Cancer Res Clin Oncol. 2009; 135(7): 909-917.
2) Chen J, Wang M, Xi B, Xue J, He D, Zhang J, Zhao Y. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PLoS One. 2012;7(8):e42413. Epub 2012 Aug 3.
3)Chen J, Shi D, Liu X, Fang S, Zhang J, Zhao Y. Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasis. BMC Cancer. 2012 Oct 10;12(1):464.
4)Chen J, Wei D, Zhao Y, Liu X, Zhang J. Overexpression of EFEMP1 Correlates with Tumor Progression and Poor Prognosis in Human Ovarian Carcinoma. PLoS One. 2013 Nov 13;8(11):e78783.
5)Chen J, Zhang J, Liu X, Fang R, Zhao Y, Ma D. Overexpression of fibulin-4 is associated with tumor progression and poor prognosis in patients with cervical carcinoma. Oncol Rep. 2014 Jun;31(6):2601-10.
6)Chen J, Liu Z, Fang S, Fang R, Liu X, Zhao Y, Li X, Huang L, Zhang J. Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas. BMC Cancer. 2015 Mar 4;15:91.
窗体顶端
窗体底端
7)Yin X, Fang S, Wang M, Wang Q, Fang R,Chen J (Corresponding author). EFEMP1 promotes ovarian cancer cell growth, invasion and metastasis via activated the AKT pathway.Oncotarget. 2016 Jul 26;7(30):47938-47953.
窗体底端
8) Wang T, Wang M, Fang S, Wang Q, Fang R, Chen J (Corresponding author). Fibulin-4 is associated with prognosis of endometrial cancer patients and inhibits cancer cell invasion and metastasis via Wnt/β-catenin signaling pathway.Oncotarget. 2017 Mar 21;8(12):18991-19012.
9) Xie J, Yang Y, Sun J, Jiao Z, Zhang H,Chen J (Corresponding author). STEAP1 Inhibits Breast Cancer Metastasis and Is Associated With Epithelial-Mesenchymal Transition Procession. Clin Breast Cancer. 2019 Feb;19(1):e195-e207.
10) Sun J, Ji G, Xie J, Jiao Z, Zhang H, Chen J (Corresponding author). Six-transmembrane epithelial antigen of the prostate 1 is associated with tumor invasion and migration in endometrial carcinomas. J Cell Biochem. 2019 Feb 3. doi: 10.1002/jcb.28393.
